Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients (pts) with advanced neuroendocrine tumors: Multivariate analysis of progression-free survival from the RADIANT-2 trial.
Philippe Ruszniewski
Employment or Leadership Position - Ipsen (I); MDD (I)
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Paola Tomassetti
No relevant relationships to disclose
Stephen Saletan
Employment or Leadership Position - Novartis
Ashok Panneerselvam
Employment or Leadership Position - Novartis
James Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech; Novartis